Pith. sign in

REVIEW 4 major objections 3 minor 19 references

GraphSeqLM: A Unified Graph Language Framework for Omic Graph Learning

T0 review · 4 major / 3 minor · reviewed 2026-08-11 · deepseek-v4-flash

Pith's one-line read A unified graph-language framework that enriches multi-omic signaling graphs with DNA, RNA, and protein sequence embeddings from LLMs reports improved patient-outcome prediction across six cancer types.

desk verdict Reasonable feature-augmentation idea, but the 'consistently outperforms' claim is contradicted by the paper's own Table 2, and missing ablations and significance tests leave the main result unverified. read the letter →

arxiv 2412.15790 v1 pith:Z62DTCXT submitted 2024-12-20 q-bio.QM cs.AIcs.LG

classification q-bio.QMcs.AIcs.LG
keywords LargelanguagemodelsGraphneuralnetworksMulti-omicdataBiologicalsequencesPrecisionmedicineCancersurvivalpredictionKnowledgegraphsSequenceembeddings
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

GraphSeqLM aims to show that enriching a multi-omic signaling knowledge graph with DNA, RNA, and protein sequence embeddings from large language models improves graph-neural-network prediction of cancer patient survival. The framework builds a KEGG-derived graph whose nodes carry fused omic features and sequence embeddings, then applies two-stage message passing to classify patients as survivors or non-survivors. On a cohort of 826 samples across six cancer types, the authors report accuracy and F1 scores that beat four standard GNN baselines on most datasets. If the claim holds, the approach provides a simple, general feature-augmentation recipe for omic graph models, with direct relevance to precision medicine.

What carries the argument

The central object is the sequence-attributed Multi-Omic Signaling Knowledge Graph (MOS-KG), where each gene, transcript, or protein node holds a multi-omic feature vector fused with a fixed LLM sequence embedding. The argument runs on two-stage message passing: an internal GNN propagates information along the translation subgraph connecting gene, transcript, and protein nodes, and a global GNN then propagates over the full KEGG regulatory and protein-protein interaction network; node embeddings are average-pooled and passed to an MLP for binary survival classification. The sequence embeddings are the new ingredient because they are the only node features not derived from the sample-specific omic measurements.

What would settle it

Retrain GraphSeqLM with the same node features but randomly permuted edge sets, preserving node degrees, and check whether accuracy drops relative to the true graph. If the randomized graph matches the true-graph performance, the reported gains come from the sequence embeddings and MLP rather than the biological topology; a second check is to replace the GNN with a sequence-feature-only MLP and compare.

Watch

Extended reading notes

Core claim

The paper's central claim is that sequence-derived embeddings—computed by DNAGPT for DNA and RNA and by ProtGPT2 for proteins—carry structural and biological information that complements multi-omic node features in a signaling graph, and that fusing the two before message passing makes the graph encoder more expressive. This fusion, combined with internal-then-global message propagation over the Multi-Omic Signaling Knowledge Graph, yields the best overall predictive accuracy and F1 across the evaluated cancer datasets. The authors interpret this as evidence that LLM sequence representations can augment GNNs in a way that overcomes their expressivity limits on large, dense biological networks.

Load-bearing premise

The load-bearing premise is that the KEGG-derived signaling graph captures the biological mechanisms that actually determine patient outcomes; if its edges are incomplete, noisy, or irrelevant to survival, message passing over that graph can dilute rather than sharpen the predictive signal.

Editorial extensions

If this is right

  • Sequence embeddings can be dropped into existing GNN-based omic models as node-level feature augmentation without changing the graph construction pipeline.
  • Across the six cancer types analyzed, the largest reported accuracy gains appear in GBM and SKCM, where the fused model surpasses the strongest baseline by several percentage points.
  • The same two-stage message-passing design could be applied to any disease with multi-omic data and a known signaling or interaction network.
  • GraphSeqLM's reliance on frozen, pretrained biological LLMs means a wide range of encoders can be swapped in as better sequence models become available.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • A natural ablation the paper does not report is to compare GraphSeqLM against a non-graph MLP using the same omic features and sequence embeddings; if the MLP matches the graph model, the biological topology contributes little beyond the features.
  • Because the reported standard deviations overlap across folds for some cancer types (e.g., LUAD and STAD), a permutation test or repeated cross-validation would clarify whether the improvements are statistically reliable.
  • The fusion of sequence and omic features is done by simple concatenation after projection; an attention-based cross-modality layer could be a direct extension and might yield larger gains.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 3 minor

Summary. The manuscript proposes GraphSeqLM, a framework that augments a multi-omic signaling knowledge graph (MOS-KG) with DNA, RNA, and protein sequence embeddings from GPT-based sequence language models (DNAGPT and ProtGPT2), then applies a two-stage GNN message-passing scheme (internal then global) and an MLP readout to predict binary overall-survival status. The method is evaluated on 826 samples across six TCGA cancer types with 5-fold cross-validation, comparing accuracy and F1 against GCN, GAT, GIN, and UniMP. The paper claims that GraphSeqLM consistently outperforms these baselines and that the LLM sequence embeddings are responsible for the improvement.

Significance. If the stated claims were established, the work would offer a plausible route to incorporate biological sequence information into interpretable multi-omic graph models, and the use of pretrained DNA/RNA/protein encoders as node-feature augmentations is timely. The manuscript also has strengths: it uses public benchmark data, standard baselines, 5-fold cross-validation, provides a code repository link, and makes the graph-construction pipeline explicit via MOS-KG/KEGG. However, the current evidence does not support the central claim: the paper's own Table 2 shows that GraphSeqLM is not consistently better than the baselines, no significance tests are reported, and no ablation isolates the contribution of the sequence embeddings. As a result the contribution, while potentially interesting, is not established.

major comments (4)
  1. [Table 2 / Section 3.2] The central claim that GraphSeqLM 'consistently outperforms other graph-based encoder models' is contradicted by Table 2. On LUAD, GraphSeqLM's accuracy is 0.6746±0.0352 and F1 is 0.5918±0.1688, while GIN achieves 0.6867±0.0714 accuracy and 0.6770±0.0335 F1; on STAD, GraphSeqLM's accuracy is 0.6734±0.0766 and F1 is 0.3319±0.1847, while UniMP achieves 0.6831±0.0619 accuracy and GIN achieves 0.4132±0.2433 F1. The wording in Sections 1, 3.2, and 4 therefore overstates the results as reported.
  2. [Section 3.2 / Table 2] No statistical significance testing accompanies any comparison. Many F1 estimates have standard deviations above 0.2 (e.g., SKCM F1: GraphSeqLM 0.5332±0.3706 vs GIN 0.4633±0.2931; BLCA F1: GAT 0.7138±0.263), so the apparent improvements on BLCA, GBM, LUSC, and SKCM could arise from fold-level noise. Paired tests across the five folds or repeated-seed comparisons are required before any claim of superiority can be made.
  3. [Section 2.2] The design does not isolate the effect of LLM sequence embeddings. Compared with the GNN baselines, GraphSeqLM changes several factors simultaneously: the node features (LLM embeddings), the CrossModalityEncoder fusion, the two-stage message-passing scheme (GNNin then GNNglobal), and the final readout. Without an ablation that runs the same two-stage architecture with and without the sequence embeddings, or a baseline that uses sequence embeddings without the graph, the paper's stated mechanism — that LLM embeddings enhance expressivity — is confounded with the architectural changes.
  4. [Section 3.1] The sample exclusion criteria are unspecified: the text says samples with 'imbalanced or insufficient data' were excluded, but it does not define these thresholds, report how many samples were removed per cancer type, or state whether exclusion was performed before or after label assignment. In addition, training hyperparameters (learning rate, number of layers, hidden dimensions d_l, d_l', and d, dropout, early stopping) and the train/validation split procedure are not reported, preventing replication and making it impossible to assess whether the comparison is fair to all methods.
minor comments (3)
  1. [Section 3.2] The heading 'Experiment Settings and Evaludation' contains a typo; 'Evaludation' should be 'Evaluation'.
  2. [Equations (9)-(10)] The AVG aggregation in Equation (9) is not defined precisely; it should specify whether the average is taken over all node embeddings or over a particular subset, and how the resulting patient-level vector is formed before the MLP.
  3. [References] Some references are informal or not clearly connected to the method as used; for example, reference [17] describes mosGraphGen, but the manuscript does not state whether that tool generated the exact MOS-KG used here, and reference [3] is a preprint that is not cited in the main text.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: GraphSeqLM's central claim is an empirical benchmark against external baselines, not a result forced by definition, fitted inputs, or same-author uniqueness theorems.

full rationale

The paper's central claim is that adding LLM sequence embeddings to multi-omic signaling graphs improves patient outcome prediction. This claim is supported by Table 2, which reports 5-fold cross-validated accuracy and F1 for GraphSeqLM against external GNN baselines (GAT, GCN, GIN, UniMP) on six cancer cohorts. The model pipeline in Eqs. (1)-(10) is a composition of external pretrained sequence encoders (DNAGPT, ProtGPT2), a KEGG-derived knowledge graph, and standard GNN message passing. No equation defines the predicted outcome as an input feature, no parameter is fitted to the benchmark labels and then relabeled as a prediction, and no same-author uniqueness theorem is invoked to force the architecture. The self-citations (refs [3], [17], [18]) appear in the introduction as general support for the value of MOS-KGs and GNNs; they are not load-bearing for the specific accuracy comparisons, which are measured against external baselines. Concerns about missing significance tests, missing ablations, and the fact that Table 2 does not support 'consistently outperforms' on LUAD and STAD are experimental-validity or correctness issues, not circularity. The derivation is therefore self-contained with respect to circularity.

Assumptions & free parameters 2 free parameters · 4 assumptions · 0 invented entities

The central empirical claim rests on the correctness of the KEGG graph as a biological model, the informativeness of the sequence embeddings, and the integrity of the evaluation setup. These are domain assumptions rather than derived results; none are tested with controls.

free parameters (2)
  • unreported training hyperparameters = not stated
    Learning rate, hidden dimensions, number of GNN layers, dropout, and optimizer settings are not specified for GraphSeqLM or baselines, making the reported scores dependent on undisclosed choices.
  • sample exclusion criteria = not stated
    Samples with imbalanced or insufficient data are excluded, but the threshold is not defined, and this changes the cohort composition.
assumptions (4)
  • domain assumption The KEGG-based knowledge graph edges represent the true regulatory and protein-protein interactions relevant to patient outcomes.
    Section 2.1 constructs G=(V,E) from KEGG; if the graph is noisy or incomplete, GNN message passing can degrade predictions. No null-graph or random-graph control is run.
  • domain assumption DNAGPT and ProtGPT2 sequence embeddings capture properties that complement the multi-omic features for survival classification.
    Section 2.2 introduces sequence encoders, but no analysis is provided to show that these embeddings add predictive information beyond the omic features themselves.
  • domain assumption Multi-omic features from UCSC Xena can be mapped one-to-one to gene, transcript, and protein nodes in the graph.
    Cross-modality fusion in Equation (6) requires aligned node identities; misalignment would corrupt the node features.
  • standard math Five-fold cross-validation on random splits provides unbiased estimates of classification performance.
    Standard evaluation practice, but the paper does not discuss whether patients are related (e.g., same study) or whether preprocessing is done inside each fold, so data leakage is a risk.

how reviews work

0 comments
Cite this review

Pith. "Pith review of GraphSeqLM: A Unified Graph Language Framework for Omic Graph Learning." pith.science (2026). https://pith.science/paper/Z62DTCXT

@misc{pith2026241215790,
  author       = {Pith},
  title        = {Pith review of: GraphSeqLM: A Unified Graph Language Framework for Omic Graph Learning},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/Z62DTCXT}},
  note         = {Machine review of arXiv:2412.15790}
}
read the original abstract

The integration of multi-omic data is pivotal for understanding complex diseases, but its high dimensionality and noise present significant challenges. Graph Neural Networks (GNNs) offer a robust framework for analyzing large-scale signaling pathways and protein-protein interaction networks, yet they face limitations in expressivity when capturing intricate biological relationships. To address this, we propose Graph Sequence Language Model (GraphSeqLM), a framework that enhances GNNs with biological sequence embeddings generated by Large Language Models (LLMs). These embeddings encode structural and biological properties of DNA, RNA, and proteins, augmenting GNNs with enriched features for analyzing sample-specific multi-omic data. By integrating topological, sequence-derived, and biological information, GraphSeqLM demonstrates superior predictive accuracy and outperforms existing methods, paving the way for more effective multi-omic data integration in precision medicine.

Figures

Figures reproduced from arXiv: 2412.15790 by the authors.

Figure 1
Figure 1. Overview of GraphSeqLM: The framework integrates multi-omic data and biological sequences into a Multi-Omic [PITH_FULL_IMAGE:figures/full_fig_p001_1.png] view at source ↗

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

19 extracted references · 11 canonical work pages

  1. [1]

    Ralph Abboud, Ismail Ilkan Ceylan, Martin Grohe, and Thomas Lukasiewicz. 2020. The surprising power of graph neural networks with random node initialization. arXiv preprint arXiv:2010.01179 (2020)

  2. [2]

    Ouyang Dong, Yong Liang, Le Li, Ning Ai, Shan Lu, Mingkun Yu, Xiaoy- ing Liu, and Shengli Xie. 2023. Integration of multi-omics data using adap- tive graph learning and attention mechanism for patient classification and biomarker identification. Computers in biology and medicine 164 (2023), 107303. https://api.semanticscholar.org/CorpusID:260590059

  3. [3]

    Zehao Dong, Qihang Zhao, Philip R. O. Payne, Michael Province, Carlos Cruchaga, Muhan Zhang, Tianyu Zhao, Yixin Chen, and Fuhai Li. 2023. Highly accurate dis- ease diagnosis and highly reproducible biomarker identification with PathFormer. Research Square (2023). https://api.semanticscholar.org/CorpusID:265462009

  4. [4]

    Noelia Ferruz, Steffen Schmidt, and Birte Höcker. 2022. ProtGPT2 is a deep unsupervised language model for protein design. Nature communications 13, 1 (2022), 4348

  5. [5]

    Mary Goldman, Brian Craft, Mim Hastie, Kristupas Repečka, Fran McDade, Akhil Kamath, Ayan Banerjee, Yunhai Luo, Dave Rogers, Angela N Brooks, et al. 2018. The UCSC Xena platform for public and private cancer genomics data visualiza- tion and interpretation. biorxiv (2018), 326470

  6. [6]

    Peter W Harrison, M Ridwan Amode, Olanrewaju Austine-Orimoloye, Andrey G Azov, Matthieu Barba, If Barnes, Arne Becker, Ruth Bennett, Andrew Berry, Jyothish Bhai, et al. 2024. Ensembl 2024. Nucleic acids research 52, D1 (2024), D891–D899

  7. [7]

    Minoru Kanehisa and Susumu Goto. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research 28, 1 (2000), 27–30

  8. [8]

    Thomas N Kipf and Max Welling. 2016. Semi-supervised classification with graph convolutional networks. arXiv preprint arXiv:1609.02907 (2016)

Show all 19 references
  1. [9]

    Xiao Li, Jie Ma, Ling Leng, Mingfei Han, Mansheng Li, Fuchu He, and Yun ping Zhu. 2022. MoGCN: A Multi-Omics Integration Method Based on Graph Convolutional Network for Cancer Subtype Analysis. Frontiers in Genetics 13 (2022). https://api.semanticscholar.org/CorpusID:246445829

  2. [10]

    Derek Lim, Joshua Robinson, Lingxiao Zhao, Tess Smidt, Suvrit Sra, Haggai Maron, and Stefanie Jegelka. 2022. Sign and basis invariant networks for spectral graph representation learning. arXiv preprint arXiv:2202.13013 (2022)

  3. [11]

    Yunsheng Shi, Zhengjie Huang, Shikun Feng, Hui Zhong, Wenjin Wang, and Yu Sun. 2020. Masked label prediction: Unified message passing model for semi- supervised classification. arXiv preprint arXiv:2009.03509 (2020)

  4. [12]

    Petar Veličković, Guillem Cucurull, Arantxa Casanova, Adriana Romero, Pietro Lio, and Yoshua Bengio. 2017. Graph attention networks. arXiv preprint arXiv:1710.10903 (2017)

  5. [13]

    Keyulu Xu, Weihua Hu, Jure Leskovec, and Stefanie Jegelka. 2018. How powerful are graph neural networks? arXiv preprint arXiv:1810.00826 (2018)

  6. [14]

    Bo Yang, Yan Yang, Meng Wang, and Xueping Su. 2023. MRGCN: cancer subtyping with multi-reconstruction graph convolutional network using full and partial multi-omics dataset. Bioinformatics 39 (2023). https://api.semanticscholar.org/ CorpusID:258988422

  7. [15]

    Lei Yu, Lei Liu, Zixian Zhang, Hengchang Zhang, and Xing Chen. 2021. MOGONET integrates multi-omics data using graph convolutional networks allowing patient classification and biomarker identification. Nature Communica- tions 12, 1 (October 2021), 6510. https://doi.org/10.1038...

  8. [16]

    Daoan Zhang, Weitong Zhang, Bing He, Jianguo Zhang, Chenchen Qin, and Jianhua Yao. 2023. DNAGPT: a generalized pretrained tool for multiple DNA sequence analysis tasks. bioRxiv (2023), 2023–07

  9. [17]

    Heming Zhang, Dekang Cao, Zirui Chen, Xiuyuan Zhang, Yixin Chen, Cole Sessions, Carlos Cruchaga, Philip Payne, Guangfu Li, Michael Province, and Fuhai Li. 2024. mosGraphGen: a novel tool to generate multi-omics signaling graphs to facilitate integrative and interpretable graph...

  10. [18]

    Heming Zhang, Yixin Chen, Philip Payne, and Fuhai Li. 2024. Using DeepSignal- ingFlow to mine signaling flows interpreting mechanism of synergy of cocktails. NPJ systems biology and applications 10 (08 2024), 92. https://doi.org/10.1038/ s41540-024-00421-w

  11. [19]

    Wenyi Zhao, Xun Gu, Shuqing Chen, Jian Wu, and Zhan Zhou. 2022. MODIG: integrating multi-omics and multi-dimensional gene network for cancer driver gene identification based on graph attention network model. Bioinformatics (2022). https://api.semanticscholar.org/CorpusID:252199074

Pith tools

Reviewed August 11, 2026 · model on record in the stance chip above.